HC Wainwright & Co. Reiterates Neutral on Outlook Therapeutics, Maintains $0.5 Price Target
Outlook Therapeutics, Inc. +5.53%
Outlook Therapeutics, Inc. OTLK | 0.27 | +5.53% |
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:
OTLK) with a Neutral and maintains $0.5 price target.
